尊龙凯时·(中国区)人生就是搏!

EN
×
EN
  • 业务咨询

    中国:

    Email: marketing@www.vi-home.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×

搜索结果包含 ARi 的内容

Aug 21,2023
TAK-931是一种高效的CDC7抑制剂,通过抑制CDC7来抑制DNA复制,具有抗肿瘤功效,体内药效研究通过尊龙凯时进行
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell divis
查看更多
Jul 06,2023
Y180是一种口服Mpro抑制剂,可有效对抗野生型SARS-CoV-2及其变种。Y180在小鼠、大鼠和狗中具有良好的PK特性
Y180, an orally available Mpro inhibitor, is effective against wild-type SARS-CoV-2 and variants. Y180 displayed satisfying PK properties in mice, rats and dogs, with oral bioavailabilities of 92.9%,
查看更多
Jul 06,2023
基于构效关系分析,合成了一种结构简化但具有优异防污活性的化合物。优化后的化合物通过尊龙凯时合成
Biofouling poses one of the most serious problems to marine industry and aquaculture development. Five structurally similar compounds were isolated from the crude extract of a marine Streptomyces stra
查看更多
Jul 06,2023
PTX-HSN是一种高效纳米系统,具有较高耐受剂量,可将PTX递送至卵巢癌并增强主动肿瘤靶向性。此研究中所有体内实验均通过尊龙凯时进行
Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,
查看更多
Jul 06,2023
AD80是一种多激酶抑制剂,在多种肝细胞癌临床前动物模型中具有抗肿瘤活性,AD80在血浆中的含量通过尊龙凯时进行LC-MS/MS测定
Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
查看更多
Jul 05,2023
合成具有体内抗肿瘤活性的强效PD-L1抑制剂,并进行生物学评价和机制研究。PK研究通过尊龙凯时进行
PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified com
查看更多
Jul 05,2023
设计、合成和评估具有体内抗炎活性的RIPK1抑制剂,PK研究通过尊龙凯时进行
RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, researchers r
查看更多
Aug 26,2016
FDA授予卵巢癌候选药物Rucaparib优先审评资格
FDA授予卵巢癌候选药物 Rucaparib 优先审评资格
查看更多
Mar 31,2015
尊龙凯时成功在韩国首尔举办CFDA IND研讨会
2015年3月18日,尊龙凯时与韩国药品制造商协会(KPMA)在韩国首尔举办CFDA IND研讨会。本次研讨会的主题是“Experience Sharing and Exchange on CFDA’s IND Application and Drug Development Collaboration” 。
查看更多
×
搜索验证